# BATCH2-ACTIVATION-1 — Runtime Activate Cleared Non-Thyroid Batch 2 Subset

**Work ID:** `BATCH2-ACTIVATION-1_runtime_activate_cleared_non_thyroid_subset`  
**Date:** 2026-06-07  
**SOP:** AUTOMATION_BUS_SOP_v1.3.1

---

## Executive verdict

**STOP GATE — READY_FOR_HUMAN_STOP_GATE.** Phase 1 preflight **PASS**. **No runtime activation performed** — human approval phrase not received in this session. **6/6** activation candidate packages validate. **4** thyroid packages remain runtime-deferred with TSH-gated blockers (clinical sign-off **APPROVE_SUBSET** ingested). **10** excluded packages confirmed untouched. Architecture gate **PASS**. Sprint closes as: **governance preflight complete / runtime activation deferred pending approval**.

---

## Preflight findings

| # | Check | Result |
|---|-------|--------|
| 1 | Six activation candidate packages found | **Yes** |
| 2 | Four thyroid packages deferred with correct blocker | **Yes** — TSH-gating blockers per clinical sign-off |
| 3 | Ten excluded packages confirmed out of scope | **Yes** |
| 4 | All six candidate packages validate | **6/6 PASS** |
| 5 | Activation keys unique | **Yes** |
| 6 | No active duplicate activation key | **Yes** |
| 7 | Runtime activation mechanism identified | **Yes** — frame index + manifest metadata only; no code changes |
| 8 | Exact files expected to change on activation | Frame index (6 frames), 6 manifests (metadata), execution register |
| 9 | Rollback path defined | **Yes** |
| 10 | No medical logic change required | **Confirmed** |

**Baseline:** `main` aligned with `origin/main` at `c0c2774`. Sprint branch: `work/BATCH2-ACTIVATION-1-runtime-activate-cleared-non-thyroid-subset`.

**Stash:** empty — no triage required.

**Thyroid clinical sign-off ingested:** `docs/Medical Research Documents/thyroid_blood_marker_interpretation_clinical_signoff.md` — overall verdict **APPROVE_SUBSET**; TSH mandatory before all four thyroid patterns; FT3 low additionally requires TSH + FT4 + illness/medication context.

---

## STOP gate outcome

**Status:** `READY_FOR_HUMAN_STOP_GATE`

**Human approval received:** **No**

**Required approval phrase:** `APPROVE BATCH2 RUNTIME ACTIVATION`

**Activation performed:** **No**

**Explicit statement:** Runtime activation has **not** been performed. No `medical_frame_identity_index_v1.yaml` or package manifest activation metadata changes were applied.

---

## Six runtime activation candidates

| package_id | activation_key | validator |
|------------|----------------|-----------|
| pkg_kb47_creatine_kinase_high_exertional_muscle_injury | signal_creatine_kinase_high::inv_creatine_kinase_high_exertional_muscle_injury | PASS |
| pkg_kb47_creatine_kinase_high_persistent_nonexertional_muscle_injury | signal_creatine_kinase_high::inv_creatine_kinase_high_persistent_nonexertional_muscle_injury | PASS |
| pkg_kb47_eosinophil_pct_high_reactive_atopic_eosinophilia | signal_eosinophil_pct_high::inv_eosinophil_pct_high_reactive_atopic_eosinophilia | PASS |
| pkg_kb47_eosinophil_pct_high_secondary_or_systemic_eosinophilia | signal_eosinophil_pct_high::inv_eosinophil_pct_high_secondary_or_systemic_eosinophilia | PASS |
| pkg_kb47_eosinophils_abs_high_reactive_eosinophilic_inflammation | signal_eosinophils_abs_high::inv_eosinophils_abs_high_reactive_eosinophilic_inflammation | PASS |
| pkg_kb47_eosinophils_abs_high_hypereosinophilic_or_secondary_eosinophilia | signal_eosinophils_abs_high::inv_eosinophils_abs_high_hypereosinophilic_or_secondary_eosinophilia | PASS |

---

## Four thyroid runtime-deferred packages

| package_id | deferred_reason |
|------------|-----------------|
| pkg_kb47_free_t3_high_t3_predominant_thyrotoxicosis | thyroid_activation_requires_tsh_gating |
| pkg_kb47_free_t3_low_low_t3_syndrome | thyroid_activation_requires_tsh_ft4_and_illness_medication_context |
| pkg_kb47_free_t4_high_thyrotoxicosis_context | thyroid_activation_requires_tsh_gating |
| pkg_kb47_free_t4_low_thyroid_hormone_deficiency | thyroid_activation_requires_tsh_gating |

---

## Ten excluded packages

All androgen (8) + eGFR (2) — **confirmed untouched**, no file modifications.

---

## Proposed activation files (pending approval)

| File | Change on approval |
|------|-------------------|
| `knowledge_bus/governance/medical_frame_identity_index_v1.yaml` | 6 frames → `promotion_state: runtime_active_canonical`, `runtime_authority_status: active`, `clinical_adjudication_status: accepted_with_rationale` |
| 6 × `package_manifest.yaml` | Add `governance_runtime_activation_status: runtime_active_canonical` and activation work_id metadata |
| `knowledge_bus/governance/batch2_runtime_activation_execution_register_v1.yaml` | Record approval + activated=true |

**Runtime effect expected:** SignalRegistry loads six additional Batch 2 activation keys at runtime authority without loader code changes.

---

## Packages activated / deferred

| Category | Count | Activated |
|----------|------:|-----------|
| Activation candidates | 6 | 0 (pending approval) |
| Thyroid deferred | 4 | 0 (by design) |
| Excluded | 10 | 0 |

---

## Rollback path

No activation performed — rollback N/A for this sprint closure.

If Phase 3 activation is later approved and applied: revert frame index to `compiled_not_promoted` / `inactive` and remove manifest `governance_runtime_activation_status` for affected packages only.

---

## Validation output

**Package validators (6/6 PASS):**

```text
pkg_kb47_creatine_kinase_high_exertional_muscle_injury: ready_for_implementation: True
pkg_kb47_creatine_kinase_high_persistent_nonexertional_muscle_injury: ready_for_implementation: True
pkg_kb47_eosinophil_pct_high_reactive_atopic_eosinophilia: ready_for_implementation: True
pkg_kb47_eosinophil_pct_high_secondary_or_systemic_eosinophilia: ready_for_implementation: True
pkg_kb47_eosinophils_abs_high_reactive_eosinophilic_inflammation: ready_for_implementation: True
pkg_kb47_eosinophils_abs_high_hypereosinophilic_or_secondary_eosinophilia: ready_for_implementation: True
```

**Architecture gate:**

```text
validation_status: PASS (frame index)
validation_status: PASS (context modifier catalogue)
day_one_architecture_validation: PASS
medical_intelligence_architecture_validation: PASS
architecture_validation_gate: PASS
```

---

## Runtime authority files changed

**None** — activation not performed.

---

## Carry-forward updates

| ID | Action |
|----|--------|
| CF-BATCH2-012 | **Open** — deferred pending `APPROVE BATCH2 RUNTIME ACTIVATION` |
| CF-BATCH2-013 | **Open** — sign-off ingested; TSH-gated activation logic still required |
| CF-BATCH2-007 | Remains Open |
| CF-BATCH2-010 | Remains Open |
| CF-CONTEXT-MOD-3 | Remains Open |

---

## Final Batch 2 activation status

| Subset | Status |
|--------|--------|
| Governance promotion (10) | **Complete** |
| Runtime activation (6 candidates) | **Deferred pending STOP approval** |
| Thyroid (4) | **Deferred pending TSH-gated activation logic** |
| Androgen + eGFR (10) | **Excluded** |

---

## Confirmations

- No runtime/frontend/evaluator **code** changes
- No medical logic changes
- No excluded package file changes
- No thyroid package manifest or frame index changes

---

## Next step

Human must reply with **`APPROVE BATCH2 RUNTIME ACTIVATION`** to authorize runtime activation of the six non-thyroid candidates. Approval must be recorded in `batch2_runtime_activation_execution_register_v1.yaml` before frame index and manifest metadata updates are applied.
